Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Castor Trevor P currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This portfolio involves 1 distinct examiner and a distinct art unit, which indicates that the current prosecution activity is highly localized within the USPTO. Such a concentrated structure suggests that the applicant is pursuing a specific pharmaceutical or biotechnological claim that falls under the jurisdiction of a specific examination group.
BARRON, SEAN C is the busiest examiner for this portfolio, with the pending office action currently assigned. Because the number of distinct examiners is limited to the examiner handling the case, the prosecution strategy is entirely focused on this individual. This allows for a precise analysis of the examiner's past behavior within the art unit to inform future responses. Practitioners should prioritize understanding the examiner's specific technical expertise and common rejection types to efficiently resolve the pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.6% | +30.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037028 | METHODS FOR ASSAYING AND MEASURING THE EFFICACY OF ANTI-NAUSEA COMPOUNDS | BARRON, SEAN C | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037028 | METHODS FOR ASSAYING AND MEASURING THE EFFICACY OF ANTI-NAUSEA COMPOUNDS | BARRON, SEAN C | 15d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037028 | METHODS FOR ASSAYING AND MEASURING THE EFFICACY OF ANTI-NAUSEA COMPOUNDS | BARRON, SEAN C | 1653 | §103§112 | Final Rejection | 15d | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCastor Trevor P has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sean C Barron has the most, with 1 of Castor Trevor P's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.